Translate Bio is a clinical-stage mRNA therapeutics company developing medicines to treat diseases caused by protein or gene dysfunction and vaccines against infectious disease pathogens. Translate Bio is primarily focused on pulmonary diseases caused by insufficient protein production or diseases where a treatment that causes a reduction of certain proteins can modify the disease. The company’s lead program is a treatment for cystic fibrosis (CF) which as of April, 2020 was in a phase 1/2 clinical trial.
Translate Bio has a proprietary mRNA therapeutic platform (MRT) used to generate mRNA that encodes functional proteins. The mRNA is encapsulated in lipid nanoparticles for delivery into target cells where it will be translated into protein. The MRT platform enables the delivery of mRNA that carries instructions to produce intracellular, transmembrane and secreted proteins. mRNA sequences are optimized for efficient protein production. Optimized tissue-specific delivery vehicles are used to deliver to the targeted cell type.
Translate Bio began a collaboration and exclusive licensing agreement with Sanofi Pasteur in 2018 to develop mRNA vaccines for up to five infectious disease pathogens.
Translate Bio is producing mRNA constructs and will use its RNA platform to discover, design and manufacture SARS-CoV-2 vaccine candidates to treat COVID-19. The company will partner with Sanofi Pasteur who will provide expertise and support to further advance vaccine candidates. Translate Bio can produce 100 gram single-batch production and is building a dedicated manufacturing space to accommodate around two 250 gram batches per month.